Monthly GLP-1 Injection? Pfizer’s VESPER-3 Data Moves the Needle

Here’s something I hear constantly from patients: “I can handle the side effects, but the every-week injection is what wears me down.” It’s a real barrier — and honestly, one of the main reasons people fall off GLP-1 therapy.

Pfizer may have an answer coming down the pipe.

Their ultra-long-acting GLP-1 injection — codenamed PF’3944 — just posted new Phase 2b data (VESPER-3 trial) showing patients who switched from weekly to monthly maintenance dosing kept losing weight. No plateau. No efficacy drop-off. At 28 weeks, patients showed up to 12.3% placebo-adjusted weight loss — and the monthly schedule didn’t compromise the trajectory.

The short version: This would mean 12 shots a year instead of 52. That’s a meaningful quality-of-life difference, especially for people who’ve been on weekly injections for a year or more.

Why Monthly Dosing Matters

GLP-1 adherence is a real problem. Not because patients don’t want to lose weight — because the every-week routine eventually grinds people down. Miss a dose here, skip a week there, and the pharmacokinetics reset. Appetite comes roaring back.

A monthly injection that maintains the same weight-loss trajectory removes one of the biggest friction points in chronic obesity treatment.

Pfizer acquired Metsera to accelerate this program and is moving full-speed-ahead: 10 Phase 3 trials are expected to launch in 2026, with a potential approval timeline in 2027–2028.

Where This Fits in the Pipeline

This isn’t the only next-gen option coming. We’ve got:

• Retatrutide (Lilly): Triple agonist, ~28% weight loss in Phase 3, approval likely 2027
• Orforglipron (Lilly): Already FDA-approved, daily oral pill, no food restrictions
• Survodutide (Boehringer/Zealand): GLP-1/glucagon dual agonist, Phase 3

Monthly dosing would add a convenience dimension that none of the current weekly injectables can claim — and compete directly with the oral options on a different axis entirely.

What This Means for CNC Patients

If monthly PF’3944 clears Phase 3, it becomes a legitimate option for patients who:

• Are stable on a weekly GLP-1 and want to reduce injection frequency
• Have dropped off therapy due to shot fatigue
• Want the efficacy of an injectable with the convenience of a once-monthly schedule

I’ll be watching the Phase 3 enrollment closely. When this data reads out, I’ll have more to say. For now — it’s another sign that the obesity medication landscape is not slowing down. If you’re on a weekly GLP-1 and feeling injection burnout, talk to us about your options. There may be more coming than you think.

Bottom line: Pfizer’s monthly GLP-1 just took a meaningful step forward. Whether it’s right for you is a conversation — not a given. But it’s one worth having.